New drugs for treating cardiac arrhythmias.
The new and potent antiarrhythmic drugs herald an exciting era in the treatment of cardiac arrhythmias. Encainide, tocainide, and mexiletine are effective in treating acute and chronic ventricular arrhythmias. Verapamil promises to be the drug of choice for paroxysmal supraventricular tachycardia. Acetubolol provides the advantages of selective beta receptor blockade and has minimal influence on pulmonary function. Aprindine and amiodarone block conduction in accessory pathways and are very suitable for treating tachycardias associated with Wolff-Parkinson-White syndrome. Ethmozin is a phenothiazine derivative with potent antiarrhythmic effects. Many of these new agents are being used with striking success abroad and at specialized treatment centers for experimental research in the United States.
D000070:Acebutolol / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D016700:Encainide; D006352:Heart Ventricles; D006801:Humans; D008801:Mexiletine / Q000627:therapeutic use; D016293:Moricizine; D009025:Morpholines / Q000627:therapeutic use; D010640:Phenothiazines / Q000627:therapeutic use; D016677:Tocainide; D014700:Verapamil / Q000627:therapeutic use
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D009025:Morpholines; D010640:Phenothiazines; D008801:Mexiletine; D016677:Tocainide; D016293:Moricizine; D001073:Aprindine; D000070:Acebutolol; D014700:Verapamil; D000638:Amiodarone; D016700:Encainide